Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Up – Here’s What Happened

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) gapped up before the market opened on Wednesday . The stock had previously closed at $24.21, but opened at $26.10. Damora Therapeutics, Inc. Common Stock shares last traded at $26.30, with a volume of 5,209 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. TD Cowen began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They issued a “buy” rating on the stock. Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 target price on the stock. Finally, HC Wainwright started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Trading Up 5.0%

The firm’s 50 day simple moving average is $23.72 and its 200-day simple moving average is $25.47. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -4.90 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the third quarter valued at approximately $76,000. Virtu Financial LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $49,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $100,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $334,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $266,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.